JP2018518978A5 - - Google Patents

Download PDF

Info

Publication number
JP2018518978A5
JP2018518978A5 JP2017568133A JP2017568133A JP2018518978A5 JP 2018518978 A5 JP2018518978 A5 JP 2018518978A5 JP 2017568133 A JP2017568133 A JP 2017568133A JP 2017568133 A JP2017568133 A JP 2017568133A JP 2018518978 A5 JP2018518978 A5 JP 2018518978A5
Authority
JP
Japan
Prior art keywords
cell according
mil
cell
antigen
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2017568133A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018518978A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/041521 external-priority patent/WO2017008019A1/en
Publication of JP2018518978A publication Critical patent/JP2018518978A/ja
Publication of JP2018518978A5 publication Critical patent/JP2018518978A5/ja
Priority to JP2021095119A priority Critical patent/JP2021121230A/ja
Withdrawn legal-status Critical Current

Links

JP2017568133A 2015-07-08 2016-07-08 キメラ抗原受容体（ｃａｒ）療法のためのｔ細胞の供給源としての骨髄浸潤リンパ球（ｍｉｌ） Withdrawn JP2018518978A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021095119A JP2021121230A (ja) 2015-07-08 2021-06-07 キメラ抗原受容体（ｃａｒ）療法のためのｔ細胞の供給源としての骨髄浸潤リンパ球（ｍｉｌ）

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562189928P 2015-07-08 2015-07-08
US62/189,928 2015-07-08
PCT/US2016/041521 WO2017008019A1 (en) 2015-07-08 2016-07-08 Marrow infiltrating lymphocytes (mils) as a source of t-cells for chimeric antigen receptor (car) therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021095119A Division JP2021121230A (ja) 2015-07-08 2021-06-07 キメラ抗原受容体（ｃａｒ）療法のためのｔ細胞の供給源としての骨髄浸潤リンパ球（ｍｉｌ）

Publications (2)

Publication Number Publication Date
JP2018518978A JP2018518978A (ja) 2018-07-19
JP2018518978A5 true JP2018518978A5 (enExample) 2019-08-15

Family

ID=57686063

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017568133A Withdrawn JP2018518978A (ja) 2015-07-08 2016-07-08 キメラ抗原受容体（ｃａｒ）療法のためのｔ細胞の供給源としての骨髄浸潤リンパ球（ｍｉｌ）
JP2021095119A Pending JP2021121230A (ja) 2015-07-08 2021-06-07 キメラ抗原受容体（ｃａｒ）療法のためのｔ細胞の供給源としての骨髄浸潤リンパ球（ｍｉｌ）

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021095119A Pending JP2021121230A (ja) 2015-07-08 2021-06-07 キメラ抗原受容体（ｃａｒ）療法のためのｔ細胞の供給源としての骨髄浸潤リンパ球（ｍｉｌ）

Country Status (12)

Country Link
US (3) US11478548B2 (enExample)
EP (1) EP3320087A4 (enExample)
JP (2) JP2018518978A (enExample)
KR (1) KR20180039068A (enExample)
CN (1) CN108026510A (enExample)
AU (1) AU2016291199B2 (enExample)
CA (1) CA2990694A1 (enExample)
HK (2) HK1254313A1 (enExample)
IL (1) IL256434B2 (enExample)
MA (1) MA42902A (enExample)
MX (1) MX2017017083A (enExample)
WO (1) WO2017008019A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017008019A1 (en) * 2015-07-08 2017-01-12 The Johns Hopkins University Marrow infiltrating lymphocytes (mils) as a source of t-cells for chimeric antigen receptor (car) therapy
GB201700621D0 (en) 2017-01-13 2017-03-01 Guest Ryan Dominic Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
WO2018209115A1 (en) * 2017-05-10 2018-11-15 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
JP2021503885A (ja) * 2017-11-22 2021-02-15 アイオバンス バイオセラピューティクス，インコーポレイテッド 末梢血からの末梢血リンパ球（ｐｂｌ）の拡大培養
EP3765094A4 (en) 2018-03-15 2021-12-22 KSQ Therapeutics, Inc. GENE REGULATORY COMPOSITIONS AND PROCEDURES FOR IMPROVED IMMUNOTHERAPY
US20210000876A1 (en) * 2018-03-22 2021-01-07 Windmil Therapeutics, Inc. Prostate Cancer Specific Marrow Infiltrating Lymphocytes and Uses Thereof
CN112638428A (zh) * 2018-06-12 2021-04-09 H·李·莫菲特癌症中心和研究所公司 嵌合抗原受体肿瘤浸润淋巴细胞
JPWO2020004337A1 (ja) * 2018-06-27 2021-08-02 国立大学法人東海国立大学機構 Ｃｄ３７特異的キメラ抗原レセプター
KR20210031898A (ko) * 2018-07-13 2021-03-23 난징 레전드 바이오테크 씨오., 엘티디. 전염병을 치료하기 위한 공동수용체 시스템
JP2022507113A (ja) * 2018-11-05 2022-01-18 ウィンドミル セラピューティクス インコーポレイテッド クローン性の増大した骨髄浸潤リンパ球およびそれらの使用
SG11202104637VA (en) * 2018-11-30 2021-06-29 Windmil Therapeutics Inc MARROW INFILTRATING LYMPHOCYTES (MILs) EXPRESSING CHIMERIC ANTIGEN RECEPTORS (CAR), METHOD OF MANUFACTURING SAME, AND METHOD OF USING IN THERAPY
CN114072158A (zh) * 2019-03-22 2022-02-18 温德弥尔治疗公司 肺癌特异性骨髓浸润淋巴细胞及其用途
JP2023507432A (ja) 2019-12-20 2023-02-22 インスティル バイオ （ユーケイ） リミテッド 腫瘍浸潤リンパ球を単離するためのデバイスおよび方法ならびにそれらの使用
US20230100744A1 (en) * 2020-02-28 2023-03-30 Windmil Therapeutics, Inc. Methods for enriching marrow infiltrating lymphocytes ("mils"), compositions containing enriched mils, and methods of using enriched mils
WO2022066872A1 (en) * 2020-09-24 2022-03-31 Windmil Therapeutics, Inc. Marrow infiltrating lymphocytes (mils) expressing t cell receptors, methods of manufacturing same, and method of using in therapy
WO2022076606A1 (en) * 2020-10-06 2022-04-14 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
CA3195019A1 (en) 2020-10-06 2022-04-14 Maria Fardis Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
WO2022098985A1 (en) * 2020-11-05 2022-05-12 Windmil Therapeutics, Inc. Glioblastoma specific marrow infiltrating lymphocytes and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014085437A2 (en) * 2012-11-27 2014-06-05 The Johns Hopkins University Use of post-transplant cyclophosphamide treated allogeneic marrow infiltrating lymphocytes to augment anti-tumor immunity
WO2010062742A2 (en) * 2008-11-03 2010-06-03 The Johns Hopkins University Methods for freparation and use of marrow infiltrating lymphocytes (mils)
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US9272002B2 (en) * 2011-10-28 2016-03-01 The Trustees Of The University Of Pennsylvania Fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
WO2013109759A1 (en) * 2012-01-17 2013-07-25 Northeastern University Methods and compositions for expanding immunosuppressive t regulatory cells in vitro and uses thereof
KR20150029714A (ko) * 2012-07-13 2015-03-18 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 이중특이적 항체의 공-도입에 의한 ｃａｒ 세포의 활성 증강
SG11201505896YA (en) * 2013-02-20 2015-09-29 Novartis Ag Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
UY35468A (es) * 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
WO2015092024A2 (en) * 2013-12-20 2015-06-25 Cellectis Method of engineering multi-input signal sensitive t cell for immunotherapy
WO2016037054A1 (en) * 2014-09-04 2016-03-10 The Johns Hopkins University Activation of marrow infiltrating lymphocytes in hypoxic alternating with normoxic conditions
MX2018000278A (es) * 2015-06-29 2018-03-08 Univ Johns Hopkins Terapia de receptores quimericos de puntos de control inmunitarios.
WO2017008019A1 (en) * 2015-07-08 2017-01-12 The Johns Hopkins University Marrow infiltrating lymphocytes (mils) as a source of t-cells for chimeric antigen receptor (car) therapy

Similar Documents

Publication Publication Date Title
JP2020508663A5 (enExample)
US11629335B2 (en) Methods of improving vector transduction efficiency into T lymphocytes
JP2020504628A5 (enExample)
US11806365B2 (en) Modified T lymphocytes comprising a CD52 antibody-inducible caspase and methods of apoptosis
JP2021035366A5 (enExample)
JP6888225B2 (ja) 改善された特異性を有する改変型ｔリンパ球
JP2017524365A5 (ja) リンパ節のｂ細胞領域、皮膚、または消化管にホーミングするように操作されたｃａｒ−ｔ細胞
JP2023011593A (ja) リンパ節のｂ細胞領域、皮膚、または消化管にホーミングするように操作されたｃａｒ－ｔ細胞
US20210154233A1 (en) MARROW INFILTRATING LYMPHOCYTES (MILs) EXPRESSING CHIMERIC ANTIGEN RECEPTORS (CAR), METHOD OF MANUFACTURING SAME, AND METHOD OF USING IN THERAPY
CN108026510A (zh) 作为用于嵌合抗原受体(car)疗法的t细胞来源的骨髓浸润淋巴细胞(mil)
AU2013204923A1 (en) Modified t lymphocytes having improved specificity
AU2024350024A1 (en) Enriched t-cell populations
Martin et al. Abstract P4-12-07: Neoadjuvant trastuzumab emtansine and docetaxel, with or without pertuzumab, in patients with HER2-positive early-stage breast cancer: Results from a phase 1b/2a study
Moser et al. Abstract CT170: Trial in progress: A phase 1, first in human clinical trial for T-Plex, a multiplexed, enhanced T cell receptor-engineered T cell therapy (TCR-T) for solid tumors
Lee et al. Induction of cancer-specific T-cell responses in patients immunized with P10s-PADRE vaccine
Rossi et al. Immunological findings in a phase II immunotherapy study using allogeneic lung cancer cells modified to express alpha (1, 3) galactosyltransferase in advanced non-small cell lung cancer (NSCLC)
HK1234782A1 (en) Methods of improving vector transduction efficiency into t lymphocytes
HK1234782B (en) Methods of improving vector transduction efficiency into t lymphocytes
Yuan et al. MTBhsp70 fusion protein targeting mesothelin augments tumor specific T cell responses and prolongs survival in a murine model of ovarian cancer
Demaria et al. Role of the PD-1/PDL-1 pathway in resistance of patients with metastatic breast cancer to treatment with radiotherapy and TGFβ neutralization
Schneble et al. Immunologic effects of a HER2 peptide (GP2) vaccine booster in previously vaccinated breast cancer patients
NZ712373B2 (en) Modified t lymphocytes
Miyabayashi et al. Cancer stem cells express specific immunogenic proteins that induce Th17-dominant immunity resulting in regression of parental tumor in vivo
NZ751539B2 (en) Modified t lymphocytes